Hallucinations. Sleep paralysis. Excessive daytime sleepiness. Jenny Lee-Gilmore was diagnosed with Type 1 narcolepsy at 21 — ...

Model Lee Hyun-yi confessed that she was diagnosed with narcolepsy, a rare and intractable disease.According to the Health ...

I feel myself weightless, but like I literally cannot move. I thought narcolepsy was what we saw on TV. I had no basis for understanding it, and I never done my own research to actually figure out ...

Narcolepsy is a sleep disorder that affects the brain ability to regulate sleep-wake cycles and it can present unique challenges for adolescents Teenagers with narcolepsy experience symptoms like exce ...

Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges ...

Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with narcolepsy. AXS-12 is an investigational highly selective potent norepinephrine reuptake ...

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is ...

NEWARK, Del, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Narcolepsy Treatment Market 2024 to 2034 is expected to experience substantial growth, with the market size projected to expand from USD 5,301.6 ...

Axsome Therapeutics has announced that its investigational narcolepsy therapy has met the primary endpoint in a Phase III trial. AXS-12 (reboxetine), the norepinephrine reuptake inhibitor and ...